Skip to main content

Advertisement

SpringerLink
Log in

Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy

  • Echocardiography (JM Gardin and AH Waller, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review discusses the complementary roles of echocardiography and cardiac magnetic resonance in the diagnosis and management of patients with hypertrophic cardiomyopathy (HCM).

Recent Findings

Imaging using novel echocardiographic techniques and cardiac magnetic resonance (CMR) imaging in HCM has demonstrated incremental utility in diagnosis and management guidance. Application of 3-D imaging has improved assessment of left ventricular (LV) mass and volume by echocardiography. Quantification of myocardial mechanics has shown promise for clarification of diagnosis, prognosis, and assessment of LV dysfunction. CMR permits 3-D tomographic characterization of cardiac structure and tissue characterization which has shown utility for assessing the diverse phenotypes in HCM and quantification of left ventricular fibrosis, an increasingly recognized poor prognostic marker.

Summary

Non-invasive cardiac imaging remains central for the evaluation of HCM patients. An approach integrating echocardiography and CMR as complementary modalities allows for improved diagnostic and prognostic assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785–9.

    Article  CAS  PubMed  Google Scholar 

  2. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699–708.

    Article  CAS  PubMed  Google Scholar 

  3. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027–35.

    Article  CAS  PubMed  Google Scholar 

  4. Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6(5):587–96.

    Article  PubMed  Google Scholar 

  5. Davies MJ. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br Heart J. 1984;51(4):361–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–15.

    Article  PubMed  Google Scholar 

  7. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65(18):1915–28.

    Article  PubMed  Google Scholar 

  8. Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399–409.

    Article  PubMed  Google Scholar 

  9. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92(6):785–91.

    Article  CAS  PubMed  Google Scholar 

  10. Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J Am Coll Cardiol. 2009;54(3):234–41.

    Article  PubMed  Google Scholar 

  11. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.

    Article  Google Scholar 

  12. American College of Cardiology Foundation/American Heart Association Task Force on P, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203.

    Article  Google Scholar 

  13. Rakowski H, Fulop J, Wigle ED. The role of echocardiography in the assessment of hypertrophic cardiomyopathy. Postgrad Med J. 1986;62(728):557–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. •• Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855–61. This sentinel paper showed the utility of CMR in identifying regions of LV hypertrophy not recognized by echocardiography and thus highlighted the role of CMR in HCM phenotype diagnosis.

    Article  PubMed  Google Scholar 

  15. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.

    Article  PubMed  PubMed Central  Google Scholar 

  16. •• Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95. This study of 1293 HCM patients showed a continuous relationship between LGE by percent LV mass and SCD event risk as well as extent of LGE was predictive of development of end-stage HCM with systolic dysfunction.

    Article  PubMed  Google Scholar 

  17. •• Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8. This study showed the emerging role of CMR in characterizing the diverse patterns of LV hypertrophy in HCM which frequently is not extensive, involving ≤50% of the LV chamber.

    Article  PubMed  Google Scholar 

  18. •• Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85. This study showed the magnitude of LV hypertrophy to directly relate to the risk of sudden death and is a strong and independent predicter of prognosis.

    Article  CAS  PubMed  Google Scholar 

  19. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41(2):315–21.

    Article  PubMed  Google Scholar 

  20. Devlin AM, Moore NR, Ostman-Smith I. A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. Br J Radiol. 1999;72(855):258–64.

    Article  CAS  PubMed  Google Scholar 

  21. Corona-Villalobos CP, Sorensen LL, Pozios I, Chu L, Eng J, Abraham MR, et al. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography. Int J Cardiovasc Imaging. 2016;32(6):945–54.

    Article  PubMed  Google Scholar 

  22. Bois JP, Geske JB, Foley TA, Ommen SR, Pellikka PA. Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography. Am J Cardiol. 2017;119(4):643–50.

    Article  PubMed  Google Scholar 

  23. •• Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645–9. This paper showed the utility of CMR in identifying areas of apical hypertrophy not appreciated by echocardiography in HCM.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293–8.

    Article  PubMed  Google Scholar 

  25. Keeling AN, Carr JC, Choudhury L. Right ventricular hypertrophy and scarring in mutation positive hypertrophic cardiomyopathy. Eur Heart J. 2010;31(3):381.

    Article  PubMed  Google Scholar 

  26. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559–66.

    Article  PubMed  Google Scholar 

  27. Childs H, Ma L, Ma M, Clarke J, Cocker M, Green J, et al. Comparison of long and short axis quantification of left ventricular volume parameters by cardiovascular magnetic resonance, with ex-vivo validation. J Cardiovasc Magn Reson. 2011;13:40.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sugeng L, Mor-Avi V, Weinert L, Niel J, Ebner C, Steringer-Mascherbauer R, et al. Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference. Circulation. 2006;114(7):654–61.

    Article  PubMed  Google Scholar 

  29. Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(4):638–45.

    Article  PubMed  Google Scholar 

  30. •• Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761–73. This study highlights the importance of identifying apical aneurysms as their presence implicates adverse outcomes in HCM.

    Article  PubMed  Google Scholar 

  31. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr. 2008;21(11):1179–201. quiz 281

    Article  PubMed  Google Scholar 

  32. • Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124(1):40–7. This study showed the various mitral valve abnormalities associated with the HCM phenotype as evidenced by CMR imaging.

    Article  CAS  PubMed  Google Scholar 

  33. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85(5):1651–60.

    Article  CAS  PubMed  Google Scholar 

  34. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1):42–52.

    Article  CAS  PubMed  Google Scholar 

  35. Kim DH, Handschumacher MD, Levine RA, Choi YS, Kim YJ, Yun SC, et al. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation. 2010;122(13):1298–307.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87(5):1570–9.

    Article  CAS  PubMed  Google Scholar 

  37. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(4):1344–54.

    Article  CAS  PubMed  Google Scholar 

  38. Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart. 2008;94(10):1276–81.

    Article  CAS  PubMed  Google Scholar 

  39. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24(5):473–98.

    Article  PubMed  Google Scholar 

  40. Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D'Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280.

    Article  PubMed  Google Scholar 

  41. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101(5):668–73.

    Article  PubMed  Google Scholar 

  42. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84(3):1188–97.

    Article  CAS  PubMed  Google Scholar 

  43. Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart. 2008;94(10):1295–301.

    Article  CAS  PubMed  Google Scholar 

  44. Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg. 2010;140(2):317–24.

    Article  PubMed  Google Scholar 

  45. Bryant R 3rd, Smedira NG. Papillary muscle realignment for symptomatic left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg. 2008;135(1):223–4.

    Article  PubMed  Google Scholar 

  46. • Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2706–13. This study highlights the role of CMR in identifying the ancillary finding of apical-septal bundles as part of the HCM phenotype.

    Article  PubMed  Google Scholar 

  47. • Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(4):441–7. This study highlights the role of CMR in identifying the ancillary finding of myocardial crypts as part of the HCM phenotype.

    Article  PubMed  Google Scholar 

  48. Brouwer WP, Germans T, Head MC, van der Velden J, Heymans MW, Christiaans I, et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging. 2012;13(4):292–7.

    Article  PubMed  Google Scholar 

  49. •• Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288–94. This study showed that LV outflow tract obstruction associated with heart failure symptoms is often identified only with exercise. It demonstrates the important role of exercise echocardiography in the routine assessment of symptomatic HCM patients without LV outflow tract obstruction at rest.

    Article  CAS  PubMed  Google Scholar 

  50. •• Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303. This study demonstrated an associated between peak instantaneous LV outflow tract obstruction and unfavorable outcome.

    Article  PubMed  Google Scholar 

  51. Elliott P, Gimeno J, Tome M, McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J. 2006;27(24):3073. author reply -4

    Article  PubMed  Google Scholar 

  52. •• O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010–20. This study led to the development of a novel SCD risk prediction HCM calculator which has been encorporated in the ESC guidelines and includes multiple imaging criterions.

    Article  PubMed  Google Scholar 

  53. •• Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57(23):2346–55. This study identifed midventricular obstruction as an independent predictor of adverse outcomes, including the combined endpoint of sudden death and potentially lethal arrhythmic events.

    Article  PubMed  Google Scholar 

  54. Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J. 2013;77(9):2366–74.

    Article  PubMed  Google Scholar 

  55. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11(4):752–6.

    Article  CAS  PubMed  Google Scholar 

  56. Klues HG, Leuner C, Kuhn H. Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol. 1992;19(3):527–33.

    Article  CAS  PubMed  Google Scholar 

  57. Drinko JK, Nash PJ, Lever HM, Asher CR. Safety of stress testing in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(11):1443–4. A12

    Article  PubMed  Google Scholar 

  58. Chai P, Mohiaddin R. How we perform cardiovascular magnetic resonance flow assessment using phase-contrast velocity mapping. J Cardiovasc Magn Reson. 2005;7(4):705–16.

    Article  PubMed  Google Scholar 

  59. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111–23.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91(7):920–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216–25.

    Article  PubMed  Google Scholar 

  62. Maciver DH. A new method for quantification of left ventricular systolic function using a corrected ejection fraction. Eur J Echocardiogr. 2011;12(3):228–34.

    Article  PubMed  Google Scholar 

  63. Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7(1):11–9.

    Article  PubMed  Google Scholar 

  64. Carasso S, Yang H, Woo A, Vannan MA, Jamorski M, Wigle ED, et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: novel concepts and implications for clinical status. J Am Soc Echocardiogr. 2008;21(6):675–83.

    Article  PubMed  Google Scholar 

  65. Oki T, Mishiro Y, Yamada H, Onose Y, Matsuoka M, Wakatsuki T, et al. Detection of left ventricular regional relaxation abnormalities and asynchrony in patients with hypertrophic cardiomyopathy with the use of tissue Doppler imaging. Am Heart J. 2000;139(3):497–502.

    Article  CAS  PubMed  Google Scholar 

  66. Bayrak F, Kahveci G, Mutlu B, Sonmez K, Degertekin M. Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy. Eur J Echocardiogr. 2008;9(2):278–83.

    Article  PubMed  Google Scholar 

  67. Yang H, Sun JP, Lever HM, Popovic ZB, Drinko JK, Greenberg NL, et al. Use of strain imaging in detecting segmental dysfunction in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2003;16(3):233–9.

    Article  PubMed  Google Scholar 

  68. Pacileo G, Baldini L, Limongelli G, Di Salvo G, Iacomino M, Capogrosso C, et al. Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr. 2011;12(11):841–9.

    Article  PubMed  Google Scholar 

  69. Popovic ZB, Kwon DH, Mishra M, Buakhamsri A, Greenberg NL, Thamilarasan M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21(12):1299–305.

    Article  PubMed  Google Scholar 

  70. Debonnaire P, Thijssen J, Leong DP, Joyce E, Katsanos S, Hoogslag GE, et al. Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging. 2014;30(3):549–58.

    Article  PubMed  Google Scholar 

  71. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–60.

    Article  PubMed  Google Scholar 

  72. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH 3rd, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. 1999;99(2):254–61.

    Article  CAS  PubMed  Google Scholar 

  73. Nishimura RA, Appleton CP, Redfield MM, Ilstrup DM, Holmes DR Jr, Tajik AJ. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol. 1996;28(5):1226–33.

    Article  CAS  PubMed  Google Scholar 

  74. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. 2007;116(23):2702–8.

    Article  PubMed  Google Scholar 

  75. Carasso S, Yang H, Woo A, Jamorski M, Wigle ED, Rakowski H. Diastolic myocardial mechanics in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2010;23(2):164–71.

    Article  PubMed  Google Scholar 

  76. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.

    Article  CAS  PubMed  Google Scholar 

  77. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301–7.

    Article  PubMed  Google Scholar 

  78. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014;3(3):e001002.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Yang H, Woo A, Monakier D, Jamorski M, Fedwick K, Wigle ED, et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr. 2005;18(10):1074–82.

    Article  PubMed  Google Scholar 

  80. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006;98(7):960–5.

    Article  PubMed  Google Scholar 

  81. Posina K, McLaughlin J, Rhee P, Li L, Cheng J, Schapiro W, et al. Relationship of phasic left atrial volume and emptying function to left ventricular filling pressure: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2013;15:99.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Left atrial minimum volume and reservoir function as correlates of left ventricular diastolic function: impact of left ventricular systolic function. Heart. 2012;98(10):813–20.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:65.

    Article  PubMed  PubMed Central  Google Scholar 

  84. • Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014;113(8):1394–400. This study showed CMR measures of LA remodelling and dysfunction including LA ejection fraction, LA size and age to be useful in reliably identifying HCM patients at risk for atrial fibrillation development.

    Article  PubMed  Google Scholar 

  85. Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017; 10(2).

  86. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53(3):284–91.

    Article  PubMed  Google Scholar 

  87. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8(3):545–57.

    Article  CAS  PubMed  Google Scholar 

  88. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260–4.

    Article  PubMed  Google Scholar 

  89. Saito M, Okayama H, Yoshii T, Hiasa G, Sumimoto T, Inaba S, et al. Myocardial fibrosis attenuates the effect of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 2011;57(2):207–12.

    Article  CAS  PubMed  Google Scholar 

  90. Almaas VM, Haugaa KH, Strom EH, Scott H, Smith HJ, Dahl CP, et al. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. Heart. 2014;100(8):631–8.

    Article  PubMed  Google Scholar 

  91. Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29(3):358–63.

    Article  PubMed  Google Scholar 

  92. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):875–87.

    Article  PubMed  Google Scholar 

  93. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867–74.

    Article  PubMed  Google Scholar 

  94. •• Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016;9(12):1392–402. This meta-analysis consisting of seven studies involving a total of 2993 patients showed quantitative LGE by CMR to provide prognostic value in SCD event prediction.

    Article  PubMed  Google Scholar 

  95. Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart. 2012;98(6):438–42.

    Article  PubMed  Google Scholar 

  96. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20(5):1066–72.

    Article  CAS  PubMed  Google Scholar 

  98. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr. 2000;13(12):1074–9.

    Article  CAS  PubMed  Google Scholar 

  99. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98(17):1750–5.

    Article  CAS  PubMed  Google Scholar 

  100. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105(25):2992–7.

    Article  PubMed  Google Scholar 

  101. Aly MF, Brouwer WP, Kleijn SA, van Rossum AC, Kamp O. Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2014;30(3):523–33.

    Article  PubMed  Google Scholar 

  102. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(1):119–22.

    Article  PubMed  Google Scholar 

  103. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–62.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Gange CA, Link MS, Maron MS. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Circulation. 2009;120(13):e96–7.

    Article  PubMed  Google Scholar 

  105. Stollberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr. 2004;17(1):91–100.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada

    Waseem Hindieh, Raymond Chan & Harry Rakowski

Authors
  1. Waseem Hindieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harry Rakowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harry Rakowski.

Ethics declarations

Conflict of Interest

Waseem Hindieh, Raymond Chan, and Harry Rakowski declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Echocardiography

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hindieh, W., Chan, R. & Rakowski, H. Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. Curr Cardiol Rep 19, 81 (2017). https://doi.org/10.1007/s11886-017-0897-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0897-z

Keywords

Search

Navigation